Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Completed · Phase 1 · Has a placebo group

Conditions studied: Hepatitis C Virus Infection

In brief

The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir in adults with genotype 1, 2, 3, 4 hepatitis C virus (HCV) infection. All participants will be monitored for up to 48 weeks after the last dose.

Key facts

Study ID

NCT02185794

Run by

Gilead Sciences

People needed

101

Starts

2014-06-13

Expected to finish

2015-09-28

Last updated by the study team

2020-09-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Costa Mesa, California, United States
• Study site — DeLand, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Kansas City, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Berlin, New Jersey, United States
• Study site — Marlton, New Jersey, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Knoxville, Tennessee, United States
• Study site — San Antonio, Texas, United States
• Study site — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.